Alkem Laboratories ' subsidiary Alkem Wellness has successfully completed the sale of its trade generics business through a final payment of ₹32.5 crore, bringing the total transaction value to ₹532.5 crore.

Transaction Overview

The completion of this sale represents a significant milestone in the company's corporate restructuring strategy. The transaction details are summarized below:

Business Divestiture Impact

The sale of the trade generics business marks a strategic shift for Alkem Wellness, allowing the company to focus resources on other core areas. This divestiture is part of the broader pharmaceutical industry trend where companies are streamlining their portfolios to concentrate on specific therapeutic segments.

The completion of the ₹532.5 crore transaction through the final ₹32.5 crore payment indicates that the sale was structured with multiple installments, with this being the concluding payment to finalize the deal.

Corporate Restructuring

This transaction represents one of the significant corporate actions undertaken by the Alkem group, demonstrating the company's strategic approach to portfolio optimization. The successful completion of the sale provides the company with additional financial flexibility while allowing it to exit the trade generics segment.

The finalization of this business sale concludes a major restructuring initiative that will likely influence the company's operational focus and resource allocation in the pharmaceutical sector.

Alkem Laboratories Limited has disclosed receiving a significant GST demand order from West Bengal tax authorities, totaling ₹9.72 crores for the financial year 2021-22. The pharmaceutical company made this disclosure on December 30, 2025, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Order Details

The demand order was issued by the Deputy Commissioner, Large Taxpayer Unit, Corporate Division, West Bengal, and was received by the company on December 29, 2025. The order pertains to the company's West Bengal GSTIN for FY2021-22.

The demand has been raised under the applicable provisions of the Integrated Goods and Services Tax (IGST) Act, 2017, Central Goods and Services Tax (CGST) Act, 2017, and State Goods and Services Tax (SGST) Act, 2017.

Nature of Alleged Violations

The GST demand order primarily alleges two main issues:

• Reverse Charge Mechanism: Alleged non-compliance with GST levy requirements under the reverse charge mechanism
• Input Tax Credit: Alleged excess availment of Input Tax Credit beyond permissible limits

The company has clearly stated that it does not agree with the allegations made in the demand order and intends to challenge the same through appropriate legal remedies.

Company's Response and Next Steps

Alkem Laboratories has indicated that it is in the process of taking appropriate action against the order, including filing an appeal with the relevant appellate authority. The company's response demonstrates its intention to contest the demand through established legal channels available under the GST framework.

Financial Impact Assessment

According to the company's disclosure, there is no material impact expected on the financial, operational, or other activities of the organization from this GST order. This assessment suggests that the company views the demand as contestable and expects to successfully challenge it through the appellate process.

The disclosure has been made available on the company's official website at www.alkemlabs.com , ensuring transparency and compliance with regulatory requirements for investor information.